233 results on '"Ponce Aix, Santiago"'
Search Results
2. Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations
3. Antibody drug conjugates in older patients: State of the art
4. RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion
5. Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC
6. Nazartinib for treatment-naive EGFR-mutant non−small cell lung cancer: Results of a phase 2, single-arm, open-label study
7. First-in-human study of RLY-2608, a pan-mutant and isoform selective PI3Kα inhibitor, as a single agent in patients (pts) with advanced solid tumors and in combination with fulvestrant in pts with advanced breast cancer.
8. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
9. Clinical utility of comprehensive liquid molecular profiling in patients with advanced endometrial cancer.
10. High risk of thrombosis in patients with advanced lung cancer harboring rearrangements in ROS1
11. Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial
12. Spatially preserved multi-region transcriptomic subtyping and biomarkers of chemoimmunotherapy outcome in extensive-stage small cell lung cancer
13. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
14. Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance
15. FGFR4 increases EGFR oncogenic signaling in lung adenocarcinoma, and their combined inhibition is highly effective
16. FGFR1 Cooperates with EGFR in Lung Cancer Oncogenesis, and Their Combined Inhibition Shows Improved Efficacy
17. Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer
18. Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study
19. Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non–Small Cell Lung Cancer
20. Prospective Clinical Integration of an Amplicon-Based Next-Generation Sequencing Method to Select Advanced Non–Small-Cell Lung Cancer Patients for Genotype-Tailored Treatments
21. From N-of-one to series of exceptional responders: unlocking the mystery of outliers in oncology
22. Supplementary Figure 2 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
23. Supplementary Table 2 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
24. Supplementary Table 3 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
25. Figure 2 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
26. Figure 5 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
27. Supplementary Figure 1 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
28. Supplementary Figure 4 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
29. Table 1 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
30. Figure 4 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
31. Figure 1 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
32. Supplementary Table 1 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
33. Figure 3 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
34. Supplementary Figure 5 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
35. Data from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
36. Supplementary Figure 3 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
37. Peapod FOS trial: A phase 2 clinical trial of pembrolizumab in combination with carboplatin and cabazitaxel in aggressive variant metastatic castration-resistant prostate cancer.
38. BladderGATE: Atezolizumab + intravesical BCG (bacillus Calmette-Guerin) upfront combination in patients with high risk non-muscle invasive bladder cancer (NMIBC)—Phase I-II ONCOSUR study.
39. Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
40. Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial
41. Abstract 3418: Alterations in PIK3CA/PTEN as resistance mechanisms in lung cancer patients progressing on first-line next generation EGFR/ALK tyrosine kinase inhibitors
42. Abstract 3458: Resistance to selective FGFR inhibitors in FGFR-driven urothelial cancer
43. Abstract P2-13-02: COBRA: Characteristics and Outcomes of patients with BReast cancer in phAse I trials at Gustave Roussy Cancer center
44. High-dose alectinib for RET fusion-positive non-small cell lung cancer in the Blood First Assay Screening Trial
45. MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma
46. GALLANT-1: Galectin-3 (Gal-3) inhibitor GB1211 plus atezolizumab (atezo) in patients with non–small cell lung cancer (NSCLC)—A randomized, double-blind trial.
47. Analysis of patients with relapsed small cell lung cancer (SCLC) receiving single-agent lurbinectedin in the phase 3 ATLANTIS trial.
48. Cabozantinib (C) plus atezolizumab (A) or C alone in patients (pts) with advanced non–small cell lung cancer (aNSCLC) previously treated with an immune checkpoint inhibitor (ICI): Results from Cohorts 7 and 20 of the COSMIC-021 study.
49. Prognostic Value of Clinical Staging According to TNM in Patients With SCLC: A Real-World Surveillance Epidemiology and End-Results Database Analysis
50. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.